EGFR and non-small cell lung carcinoma: The patient demonstrated substantial reduction in tumor burden, attained extended disease stability, and noted enhancements in overall quality of life, accompanied by tolerable adverse effects.<h4>Lessons</h4>Furmonertinib, as a third-generation EGFR-TKI, demonstrated substantial efficacy in patients with advanced EGFR20ins-mutant NSCLC, significantly extending PFS and improving quality of life.